Developer docs
API playgroundTry for free, no card

Search company profiles

Partner Therapeutics

Full company profile

uuid0004l23

Namestring
Partner Therapeutics
Legal namestring
Partner Therapeutics, Inc.
Websiteurl
partnertx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Partner Therapeutics (PTx) is a privately held, integrated biopharmaceutical company founded in 2017 and headquartered in Lexington, Massachusetts, with a secondary office in Lynnwood, Washington. The company develops and commercializes late-stage therapeutics for cancer and serious diseases, and develops host-directed treatments for global health security threats. Its commercial portfolio is anchored by two FDA-approved products: BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody licensed from Merus N.V. (a Genmab subsidiary) that blocks NRG1 fusion-driven oncogenic signaling and is approved for NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma; and LEUKINE (sargramostim), a yeast-derived recombinant human GM-CSF with multiple hematology/oncology indications and inclusion in the U.S. Strategic National Stockpile for acute radiation syndrome and pandemic preparedness.

The company monetizes BIZENGRI and LEUKINE through traditional specialty-pharma distribution channels in the U.S., a Named Patient Program administered by Tanner Pharma Group outside the U.S., and a partnership with Nobelpharma for SARGMALIN in Japan; non-dilutive revenue also flows from milestone-based government contracts with the DoD (JPEO-CBRND) and BARDA for medical countermeasure development. PTx serves three primary customer cohorts: (1) oncology patients with NRG1+ biomarker-defined solid tumors treated at major academic centers including Dana-Farber and Memorial Sloan Kettering; (2) hematology/oncology patients requiring myeloid reconstitution post-chemotherapy, transplant, or radiation exposure; and (3) federal agencies procuring Leukine for the Strategic National Stockpile and CBRN defense programs.

The business is supported by investigator-initiated research at the University of Colorado (Alzheimer's and Down syndrome) and the University of Nebraska (Parkinson's disease), alongside licensing collaborations with SIRS Therapeutics and F4 Pharma on FX-06 for capillary leak and pandemic indications. Operationally, PTx employs 101-250 staff and operates with no disclosed venture capital or institutional investor base beyond its 2018 funding round, suggesting founder/management-controlled ownership.

Short descriptiontext

Partner Therapeutics is a privately held Boston-area biopharmaceutical company that develops and commercializes BIZENGRI, a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE, a recombinant GM-CSF for hematology, oncology, and government medical countermeasure applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology therapeutics, bispecific antibodies, immunomodulatory drugs, medical countermeasures, hematopoietic agents
Industry3 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Revenue generated from the sale of FDA-approved prescription pharmaceuticals including BIZENGRI (zenocutuzumab-zbco) for NRG1+ cancers and LEUKINE (sargramostim) for hematopoietic/immune indications. The company commercializes drugs directly in the US market and through named-patient programs outside the US.

partnertx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1BIZENGRI
Description

BIZENGRI (zenocutuzumab-zbco) is a bispecific antibody approved for NRG1 fusion-positive cancers including NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma. It is a registered trademark of Merus B.V. licensed to Partner Therapeutics for U.S. development and commercialization.

partnertx.com
+3 more records
Core offering1 text field

Partner Therapeutics develops and commercializes FDA-approved biopharmaceutical products for cancer and serious diseases. The company markets BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a recombinant human GM-CSF for hematopoietic support and medical countermeasure applications. The company also develops host-directed therapeutic treatments for global health security threats under government contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 36.8% overall response rate in NRG1+ cholangiocarcinoma (95% CI: 16.3, 61.6%)
+2 more records
Product overview1 text field

Partner Therapeutics is an integrated biotechnology company focused on development and commercialization of late-stage therapeutics for cancer and serious diseases. The portfolio includes BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody targeting NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a GM-CSF immunomodulator with applications in oncology, acute radiation syndrome, and global health security threats.

Product and service2 records
1BIZENGRI (zenocutuzumab-zbco)
CategoryOncology Biopharmaceutical
Description

A bispecific HER2/HER3 antibody approved by the FDA for treatment of adults with advanced unresectable or metastatic solid tumors harboring NRG1 gene fusions, including non-small cell lung cancer, pancreatic adenocarcinoma, and cholangiocarcinoma. It blocks HER2/HER3 dimerization and NRG1 fusion interactions with HER3 to suppress oncogenic signaling. Partner Therapeutics holds exclusive U.S. commercialization rights licensed from Merus N.V.

2LEUKINE (sargramostim)
CategoryHematology/Immunomodulatory Biopharmaceutical
Description

A yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) with immunomodulatory properties. FDA-approved for acute myeloid leukemia, bone marrow transplantation, and acute radiation syndrome. Marketed as LEUKINE in the U.S., IMREPLYS in the EU, and SARGMALIN in Japan. Held in the U.S. Strategic National Stockpile for national biodefense preparedness.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Cholangiocarcinoma Foundation
Strategic tierMinorTypeOthersAnnounced on2026-05-06
Description

Patient advocacy organization supporting awareness and research for cholangiocarcinoma. CEO Stacie Lindsey quoted in support of BIZENGRI approval.

partnertx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-17
Description

Milestone-based Other Transaction Agreement (OTA) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to fund development and regulatory activities for Leukine to treat sulfur mustard gas exposure. Previously awarded $39.5 million for COVID-19 studies and $35 million for advanced development and EUA request for Leukine as COVID-19 treatment.

3BARDA
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Collaboration with Biomedical Advanced Research and Development Authority to advance a diagnostic approach for immunoparalyzed sepsis patients that could benefit from Leukine treatment. Partnership includes development of HLA-DR Laboratory Developed Test with Labcorp Drug Development.

careers.partnertx.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Collaboration with Labcorp Drug Development to develop and validate a quantitative flow cytometric Laboratory Developed Test (LDT) for HLA-DR protein on circulating monocytes to identify immunoparalyzed sepsis patients.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-03
Description

Licensing and collaboration agreement with Munich-based SIRS Therapeutics to support development of FX-06, a synthetic peptide with potential applications in COVID-19, pandemic, chemical, biological, radiological and nuclear threats.

6F4 Pharma
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-03-03
Description

Licensing and collaboration agreement with Vienna-based F4 Pharma to support FX-06 development for diseases associated with capillary leak and endothelial barrier integrity.

partnertx.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Under an agreement with Merus, PTx has exclusive rights to develop, manufacture, and commercialize zenocutuzumab-zbco (BIZENGRI) for the treatment of NRG1+ cancer in the U.S. and provide the product on a named-patient basis outside the U.S. pending regulatory developments.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with Nobelpharma Co. Ltd for commercialization of SARGMALIN (sargramostim) in Japan.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Jazz Pharmaceuticals previously owned LEUKINE (sargramostim) and divested it to Partner Therapeutics in 2018, making it the most directly comparable peer in terms of product history, oncology/hematology commercial focus, and rare-disease commercial model.

TypeDirect peer
Description

Merus N.V. (now a Genmab subsidiary) is the originator and licensor of zenocutuzumab (BIZENGRI), operating in the same bispecific antibody oncology niche. Both companies share the same molecular asset, making this the closest direct peer in technology and target patient population.

TypeDirect peer
Description

Genmab acquired Merus and is a global leader in bispecific antibody technology (including approved products like Rybrevant and Tecvayli). It competes directly with PTx's BIZENGRI in oncology bispecifics while sharing the underlying antibody platform via Merus.

TypeDirect peer
Description

MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics for cancer, sharing PTx's bispecific antibody approach to oncology and overlapping target patient populations in solid tumors.

TypeDirect peer
Description

Incyte is a specialty oncology and hematology company with approved products like Jakafi and a pipeline of targeted therapies, making it highly comparable in commercial stage, patient population focus (rare hematology/oncology), and specialty distribution model.

TypeDirect peer
Description

BeiGene is a global oncology biotechnology company with approved products like Brukinsa and tislelizumab. It shares PTx's commercial-stage oncology focus and pursues similar strategic partnerships and global commercialization strategies.

TypeBroad incumbent
Description

Roche is the established leader in bispecific antibodies (Hemlibra, Vabysmo) with deep oncology and hematology portfolios. It competes with PTx in the HER2/HER3 oncology space and represents a much larger, broadly diversified incumbent.

TypeBroad incumbent
Description

AstraZeneca has a major oncology franchise including bispecific antibodies (e.g., Datroway, Imfinzi) and competes broadly in NRG1, HER2/HER3, and cholangiocarcinoma markets where PTx operates, though at vastly larger scale.

TypeDirect peer
Description

Bavarian Nordic is a biodefense-focused biotech with smallpox/mpox vaccines and government stockpile contracts. It is highly comparable to PTx's LEUKINE strategy of leveraging government contracts and Strategic National Stockpile positioning for durable revenue.

TypeDirect peer
Description

Emergent BioSolutions is a biodefense-focused company with multiple BARDA contracts and Strategic National Stockpile placements. It mirrors PTx's LEUKINE biodefense franchise with similar government countermeasure business model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Partner Therapeutics

Oncology Biopharmaceuticalspartnertx.com

Partner Therapeutics is a privately held Boston-area biopharmaceutical company that develops and commercializes BIZENGRI, a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE, a recombinant GM-CSF for hematology, oncology, and government medical countermeasure applications.

What Partner Therapeutics does

Partner Therapeutics (PTx) is a privately held, integrated biopharmaceutical company founded in 2017 and headquartered in Lexington, Massachusetts, with a secondary office in Lynnwood, Washington. The company develops and commercializes late-stage therapeutics for cancer and serious diseases, and develops host-directed treatments for global health security threats. Its commercial portfolio is anchored by two FDA-approved products: BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody licensed from Merus N.V. (a Genmab subsidiary) that blocks NRG1 fusion-driven oncogenic signaling and is approved for NRG1 fusion-positive NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma; and LEUKINE (sargramostim), a yeast-derived recombinant human GM-CSF with multiple hematology/oncology indications and inclusion in the U.S. Strategic National Stockpile for acute radiation syndrome and pandemic preparedness.

The company monetizes BIZENGRI and LEUKINE through traditional specialty-pharma distribution channels in the U.S., a Named Patient Program administered by Tanner Pharma Group outside the U.S., and a partnership with Nobelpharma for SARGMALIN in Japan; non-dilutive revenue also flows from milestone-based government contracts with the DoD (JPEO-CBRND) and BARDA for medical countermeasure development. PTx serves three primary customer cohorts: (1) oncology patients with NRG1+ biomarker-defined solid tumors treated at major academic centers including Dana-Farber and Memorial Sloan Kettering; (2) hematology/oncology patients requiring myeloid reconstitution post-chemotherapy, transplant, or radiation exposure; and (3) federal agencies procuring Leukine for the Strategic National Stockpile and CBRN defense programs.

The business is supported by investigator-initiated research at the University of Colorado (Alzheimer's and Down syndrome) and the University of Nebraska (Parkinson's disease), alongside licensing collaborations with SIRS Therapeutics and F4 Pharma on FX-06 for capillary leak and pandemic indications. Operationally, PTx employs 101-250 staff and operates with no disclosed venture capital or institutional investor base beyond its 2018 funding round, suggesting founder/management-controlled ownership.

Partner Therapeutics firmographics

Firmographics
Name
Partner Therapeutics
Legal name
Partner Therapeutics, Inc.
Website
https://partnertx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Partner Therapeutics is a privately held Boston-area biopharmaceutical company that develops and commercializes BIZENGRI, a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE, a recombinant GM-CSF for hematology, oncology, and government medical countermeasure applications.
Ownership category
akta.pro rank

Partner Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAJ
Transplant & Immunosuppression Specialty Pharmaceuticals

Keywords

  • Oncology therapeutics
  • Bispecific antibodies
  • Immunomodulatory drugs
  • Medical countermeasures
  • Hematopoietic agents

Where Partner Therapeutics is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Partner Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Revenue generated from the sale of FDA-approved prescription pharmaceuticals including BIZENGRI (zenocutuzumab-zbco) for NRG1+ cancers and LEUKINE (sargramostim) for hematopoietic/immune indications. The company commercializes drugs directly in the US market and through named-patient programs outside the US.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Partner Therapeutics product offering

Product offering

Core offering

Partner Therapeutics develops and commercializes FDA-approved biopharmaceutical products for cancer and serious diseases. The company markets BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a recombinant human GM-CSF for hematopoietic support and medical countermeasure applications. The company also develops host-directed therapeutic treatments for global health security threats under government contracts.

Product overview

Partner Therapeutics is an integrated biotechnology company focused on development and commercialization of late-stage therapeutics for cancer and serious diseases. The portfolio includes BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody targeting NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a GM-CSF immunomodulator with applications in oncology, acute radiation syndrome, and global health security threats.

Differentiator

Problem solved

Functional benefit

Brands

  • BIZENGRI: BIZENGRI (zenocutuzumab-zbco) is a bispecific antibody approved for NRG1 fusion-positive cancers including NSCLC, pancreatic adenocarcinoma, and cholangiocarcinoma. It is a registered trademark of Merus B.V. licensed to Partner Therapeutics for U.S. development and commercialization.
  • LEUKINE
  • IMREPLYS
  • SARGMALIN

Products and services

  • BIZENGRI (zenocutuzumab-zbco) A bispecific HER2/HER3 antibody approved by the FDA for treatment of adults with advanced unresectable or metastatic solid tumors harboring NRG1 gene fusions, including non-small cell lung cancer, pancreatic adenocarcinoma, and cholangiocarcinoma. It blocks HER2/HER3 dimerization and NRG1 fusion interactions with HER3 to suppress oncogenic signaling. Partner Therapeutics holds exclusive U.S. commercialization rights licensed from Merus N.V.
  • LEUKINE (sargramostim) A yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhuGM-CSF) with immunomodulatory properties. FDA-approved for acute myeloid leukemia, bone marrow transplantation, and acute radiation syndrome. Marketed as LEUKINE in the U.S., IMREPLYS in the EU, and SARGMALIN in Japan. Held in the U.S. Strategic National Stockpile for national biodefense preparedness.

Quantifiable outcome

  • 36.8% overall response rate in NRG1+ cholangiocarcinoma (95% CI: 16.3, 61.6%)
  • +2 more outcomes

Companies that use Partner Therapeutics

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Partner Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Partner Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • Cholangiocarcinoma FoundationminorOthers · 6 May 2026Patient advocacy organization supporting awareness and research for cholangiocarcinoma. CEO Stacie Lindsey quoted in support of BIZENGRI approval.
  • U.S. Department of Defense (DoD) / JPEO-CBRNDcoreStrategic or Co-development Partner · 17 February 2022Milestone-based Other Transaction Agreement (OTA) with the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense to fund development and regulatory activities for Leukine to treat sulfur mustard gas exposure. Previously awarded $39.5 million for COVID-19 studies and $35 million for advanced development and EUA request for Leukine as COVID-19 treatment.
  • BARDAcoreStrategic or Co-development Partner · 20 September 2021Collaboration with Biomedical Advanced Research and Development Authority to advance a diagnostic approach for immunoparalyzed sepsis patients that could benefit from Leukine treatment. Partnership includes development of HLA-DR Laboratory Developed Test with Labcorp Drug Development.
  • Labcorp Drug DevelopmentminorStrategic or Co-development Partner · 20 September 2021Collaboration with Labcorp Drug Development to develop and validate a quantitative flow cytometric Laboratory Developed Test (LDT) for HLA-DR protein on circulating monocytes to identify immunoparalyzed sepsis patients.
  • SIRS TherapeuticsminorStrategic or Co-development Partner · 3 March 2021Licensing and collaboration agreement with Munich-based SIRS Therapeutics to support development of FX-06, a synthetic peptide with potential applications in COVID-19, pandemic, chemical, biological, radiological and nuclear threats.
  • F4 PharmaminorStrategic or Co-development Partner · 3 March 2021Licensing and collaboration agreement with Vienna-based F4 Pharma to support FX-06 development for diseases associated with capillary leak and endothelial barrier integrity.
  • Merus N.V. (Genmab subsidiary)coreOEM/ Whitelabel/ Licensing PartnerUnder an agreement with Merus, PTx has exclusive rights to develop, manufacture, and commercialize zenocutuzumab-zbco (BIZENGRI) for the treatment of NRG1+ cancer in the U.S. and provide the product on a named-patient basis outside the U.S. pending regulatory developments.
  • Nobelpharma Co. LtdminorChannel Partner/ Reseller/ DistributorPartnership with Nobelpharma Co. Ltd for commercialization of SARGMALIN (sargramostim) in Japan.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Partner Therapeutics competitors and assessment

Company assessment

Direct peers

  • Jazz Pharmaceuticals: Jazz Pharmaceuticals previously owned LEUKINE (sargramostim) and divested it to Partner Therapeutics in 2018, making it the most directly comparable peer in terms of product history, oncology/hematology commercial focus, and rare-disease commercial model.
  • Merus N.V. Merus N.V. (now a Genmab subsidiary) is the originator and licensor of zenocutuzumab (BIZENGRI), operating in the same bispecific antibody oncology niche. Both companies share the same molecular asset, making this the closest direct peer in technology and target patient population.
  • Genmab: Genmab acquired Merus and is a global leader in bispecific antibody technology (including approved products like Rybrevant and Tecvayli). It competes directly with PTx's BIZENGRI in oncology bispecifics while sharing the underlying antibody platform via Merus.
  • MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing bispecific antibodies and antibody-based therapeutics for cancer, sharing PTx's bispecific antibody approach to oncology and overlapping target patient populations in solid tumors.
  • Incyte Corporation: Incyte is a specialty oncology and hematology company with approved products like Jakafi and a pipeline of targeted therapies, making it highly comparable in commercial stage, patient population focus (rare hematology/oncology), and specialty distribution model.
  • BeiGene: BeiGene is a global oncology biotechnology company with approved products like Brukinsa and tislelizumab. It shares PTx's commercial-stage oncology focus and pursues similar strategic partnerships and global commercialization strategies.
  • Bavarian Nordic: Bavarian Nordic is a biodefense-focused biotech with smallpox/mpox vaccines and government stockpile contracts. It is highly comparable to PTx's LEUKINE strategy of leveraging government contracts and Strategic National Stockpile positioning for durable revenue.
  • Emergent BioSolutions: Emergent BioSolutions is a biodefense-focused company with multiple BARDA contracts and Strategic National Stockpile placements. It mirrors PTx's LEUKINE biodefense franchise with similar government countermeasure business model.

Broad incumbents

  • Roche: Roche is the established leader in bispecific antibodies (Hemlibra, Vabysmo) with deep oncology and hematology portfolios. It competes with PTx in the HER2/HER3 oncology space and represents a much larger, broadly diversified incumbent.
  • AstraZeneca: AstraZeneca has a major oncology franchise including bispecific antibodies (e.g., Datroway, Imfinzi) and competes broadly in NRG1, HER2/HER3, and cholangiocarcinoma markets where PTx operates, though at vastly larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Partner Therapeutics social profiles

Digital presence

Partner Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Partner Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Partner Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Partner Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Partner Therapeutics

What does Partner Therapeutics do?

Partner Therapeutics develops and commercializes FDA-approved biopharmaceutical products for cancer and serious diseases. The company markets BIZENGRI (zenocutuzumab-zbco), a bispecific HER2/HER3 antibody for NRG1 fusion-positive cancers, and LEUKINE (sargramostim), a recombinant human GM-CSF for hematopoietic support and medical countermeasure applications. The company also develops host-directed therapeutic treatments for global health security threats under government contracts.

Is Partner Therapeutics a public or private company?

Partner Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Partner Therapeutics founded?

Partner Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Partner Therapeutics based?

Partner Therapeutics is headquartered in Lexington, United States, in the North America region.

How does Partner Therapeutics make money?

One revenue line is on record: pharmaceutical product sales.

Who are Partner Therapeutics's main competitors?

Direct peers on record are Jazz Pharmaceuticals, Merus N.V., Genmab, MacroGenics, Incyte Corporation, BeiGene, Bavarian Nordic and Emergent BioSolutions. Broad incumbents are Roche and AstraZeneca.

Does Partner Therapeutics have an API?

No public API is recorded for Partner Therapeutics.

What industry is Partner Therapeutics in?

Partner Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OncLiveFDA Approval Is Sought for Zenocutuzumab in NRG1+ CholangiocarcinomaPartner Therapeutics submitted a supplemental biologics license application to the FDA for zenocutuzumab in NRG1 fusion–positive cholangiocarcinoma, and the NCCN added it as a Category 2A subsequent-line and Category 2B frontline therapy. The eNRGy study reported an overall response rate of 36.8% and a median duration of response of 12.9 months.pharmaphorumPartner's Bizengri is first drug for rare, aggressive cancerPartner Therapeutics' Bizengri received FDA approval for a new indication in NRG1 fusion-positive cholangiocarcinoma, two days after a Commissioner's National Priority Voucher. The approval follows a single-arm trial of 19 patients showing a 36.8% overall response rate. The FDA will hold a public meeting on 4 June to discuss the voucher programme.PrecisionmedicineonlineCritics Raise Transparency Concerns Over FDA National Priority Voucher ProgramStakeholders urged the US Food and Drug Administration to clarify eligibility criteria for the Commissioner's National Priority Voucher (CNPV) pilot program during a public hearing, with critics raising concerns about political influence, vague national priority criteria, and the program's lack of congressional authorization. The FDA has already awarded CNPVs to several precision medicines, including Regeneron Pharmaceuticals' Otarmeni, Partner Therapeutics' Bizengri, and Boehringer Ingelheim's Hernexeos, which received expedited review under the initiative launched by former Commissioner Marty Makary in June 2025. Industry groups including PhRMA called for formal notice-and-comment rulemaking to establish clear guardrails, while consumer advocacy organizations CSPI and Doctors for America urged the agency to wind down the program.FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from expertsThe FDA held its first public hearing on June 4 for the Commissioner's National Priority Voucher (CNPV) pilot program, where industry representatives largely voiced support while physicians, public health experts, and ethicists expressed deep concerns about politicization, lack of transparency, and procedural integrity. Major pharmaceutical companies including Johnson & Johnson, Merck & Co., and Partner Therapeutics shared positive experiences with the program, citing accelerated review times—Partner noted Bizengri's review was cut from 10 months to six weeks—though critics highlighted that 10 of the 22 vouchers awarded so far went to companies with White House drug pricing deals. Public comments will be accepted until June 29 and will directly inform how the FDA evaluates the program's future.MedCity NewsAstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast CancerThe FDA approved Datroway, a Daiichi Sankyo and AstraZeneca antibody-drug conjugate, as first-line treatment for triple negative breast cancer. Phase 3 data showed a 43% reduction in disease progression or death versus chemotherapy, with median progression-free survival of 10.8 months versus 5.6 months. The approval is accelerated, pending confirmatory study data.Pharmaceutical TechnologyRegulatory round-up: A month of key FDA approvals for cancer drugsThe FDA approved four oncology drugs in May 2026 across haematological and solid tumour indications. Taiho Oncology secured approval for Inqovi (decitabine/cedazuridine) plus venetoclax in newly diagnosed AML; BeOne Medicines received accelerated approval for Beqalzi (sonrotoclax) in relapsed or refractory mantle cell lymphoma; Arvinas gained approval for Veppanu (vepdegestrant) plus Guardant360's companion diagnostic for ESR1-mutated breast cancer; and Partner Therapeutics obtained accelerated approval for Bizengri (zenocutuzumab) in bile duct cancer.MedCity NewsA Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved TherapyThe FDA approved Bizengri, an intravenous bispecific antibody from Partner Therapeutics, for treating adults with NRG1 gene fusion-positive cholangiocarcinoma that progressed on prior therapy. The approval was based on a trial of 22 patients, with a 36.8% overall response rate. The drug is the seventh product approved under the CNPV pilot program.BioSpacePartner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucherThe FDA approved Partner Therapeutics' Bizengri for adults with cholangiocarcinoma carrying an NRG1 gene fusion, making it the first FDA-approved therapy for this specific cancer and the seventh drug approved under the Commissioner's National Priority Voucher program. The approval came just days after Bizengri was awarded the priority voucher, which accelerates regulatory review timelines. Clinical data from a single-arm study of 19 patients showed an overall response rate of 36.8%, with duration of response ranging from 2.8 to 12.9 months.FiercePharmaPartner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancerThe FDA approved Partner Therapeutics' bispecific antibody Bizengri for second-line treatment of advanced cholangiocarcinoma with NRG1 gene fusion, marking the drug's third indication. The approval, granted under the CNPV pilot, cites a 36.8% response rate in a midphase trial. The program's public hearing is set for June 4.AijournPartner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority VoucherPartner Therapeutics announced FDA approval of BIZENGRI (zenocutuzumab-zbco) for adults with advanced NRG1 fusion-positive cholangiocarcinoma, making it the first targeted therapy specifically approved for this molecularly defined cancer. The approval was based on the eNRGy Phase 2 trial showing a 36.8% overall response rate with duration of response ranging from 2.8 to 12.9 months among 19 evaluable patients. The review was expedited by PTx's receipt of a Commissioner’s National Priority Voucher, and BIZENGRI had previously received accelerated approval for NRG1+ non-small cell lung cancer and pancreatic adenocarcinoma.